As of 2024-12-11, the EV/EBITDA ratio of Ocular Therapeutix Inc (OCUL) is -8.18. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. OCUL's latest enterprise value is 1,124.75 mil USD. OCUL's TTM EBITDA according to its financial statements is -137.53 mil USD. Dividing these 2 quantities gives us the above OCUL EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 7.6x - 10.0x | 8.6x |
| Forward P/E multiples | 13.2x - 19.2x | 16.6x |
| Fair Price | (9.26) - (6.46) | (8.74) |
| Upside | -198.1% - -168.4% | -192.5% |
| Date | EV/EBITDA |
| 2024-12-05 | -8.00 |
| 2024-12-04 | -8.22 |
| 2024-12-03 | -8.24 |
| 2024-12-02 | -8.56 |
| 2024-11-29 | -8.69 |
| 2024-11-27 | -8.89 |
| 2024-11-26 | -8.53 |
| 2024-11-25 | -7.78 |
| 2024-11-22 | -7.48 |
| 2024-11-21 | -7.13 |
| 2024-11-20 | -7.42 |
| 2024-11-19 | -7.58 |
| 2024-11-18 | -7.32 |
| 2024-11-15 | -7.86 |
| 2024-11-14 | -8.73 |
| 2024-11-13 | -9.50 |
| 2024-11-12 | -9.50 |
| 2024-11-11 | -9.92 |
| 2024-11-08 | -10.08 |
| 2024-11-07 | -9.71 |
| 2024-11-06 | -9.89 |
| 2024-11-05 | -9.47 |
| 2024-11-04 | -9.13 |
| 2024-11-01 | -9.26 |
| 2024-10-31 | -9.42 |
| 2024-10-30 | -10.05 |
| 2024-10-29 | -10.30 |
| 2024-10-28 | -10.38 |
| 2024-10-25 | -10.12 |
| 2024-10-24 | -9.84 |
| 2024-10-23 | -9.80 |
| 2024-10-22 | -10.30 |
| 2024-10-21 | -10.38 |
| 2024-10-18 | -10.34 |
| 2024-10-17 | -10.06 |
| 2024-10-16 | -10.50 |
| 2024-10-15 | -9.08 |
| 2024-10-14 | -9.34 |
| 2024-10-11 | -8.57 |
| 2024-10-10 | -7.93 |
| 2024-10-09 | -8.02 |
| 2024-10-08 | -8.04 |
| 2024-10-07 | -8.22 |
| 2024-10-04 | -8.64 |
| 2024-10-03 | -7.94 |
| 2024-10-02 | -8.03 |
| 2024-10-01 | -7.74 |
| 2024-09-30 | -7.33 |
| 2024-09-27 | -7.31 |
| 2024-09-26 | -7.42 |